At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
LY2523355 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 2 Study of LY2523355 Versus Ixabepilone in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Received Prior Taxane Therapy
In Brief
A Phase 2 clinical trial evaluating LY2523355, ixabepilone, and 2 other interventions for Metastatic Breast Cancer. Completed, enrolled 39 participants across 12 sites.
Detailed Summary
The purpose of the study is to evaluate the anti-tumor activity of LY2523355 relative to ixabepilone for the treatment of metastatic or locally recurrent breast cancer using change in tumor size as a continuous measure of response.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedAug 2011
Primary CompletionAug 2012
Study CompletionSep 2013
TodayJul 2026
First PostedAug 15, 2011
Enrollment StartAug 1, 2011
Primary CompletionAug 1, 2012
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.9 years ago
Interventions
LY2523355drug
Administered intravenously as a one hour infusion
ixabepilonedrug
Administered intravenously
pegfilgrastimdrug
Administered intravenously
filgrastimdrug
Administered intravenously